Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2017, Article ID 4521324, 14 pages
https://doi.org/10.1155/2017/4521324
Research Article

TNF-α Induced the Enhanced Apoptosis of Mesenchymal Stem Cells in Ankylosing Spondylitis by Overexpressing TRAIL-R2

1Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107 Yan Jiang Road West, Guangzhou 510120, China
2Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107 Yan Jiang Road West, Guangzhou 510120, China
3Institute of Orthopaedics and Traumatology, The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou 510150, China

Correspondence should be addressed to Yanfeng Wu; moc.621@ncgnefnayuw and Huiyong Shen; moc.nuyila@gnoyiuhnehs

Received 22 July 2016; Accepted 4 December 2016; Published 15 January 2017

Academic Editor: Silvia Brunelli

Copyright © 2017 Zhenhua Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Dougados and D. Baeten, “Spondyloarthritis,” The Lancet, vol. 377, no. 9783, pp. 2127–2137, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Bowness, “HLA-B27,” Annual Review of Immunology, vol. 33, pp. 29–48, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. J. D. Reveille, A.-M. Sims, P. Danoy et al., “Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci,” Nature Genetics, vol. 42, no. 2, pp. 123–127, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. J. D. Taurog, J. A. Richardson, J. T. Croft et al., “The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats,” Journal of Experimental Medicine, vol. 180, no. 6, pp. 2359–2364, 1994. View at Publisher · View at Google Scholar · View at Scopus
  5. M.-E. Costello, F. Ciccia, D. Willner et al., “Brief Report: intestinal dysbiosis in ankylosing spondylitis,” Arthritis and Rheumatology, vol. 67, no. 3, pp. 686–691, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Rashid and A. Ebringer, “Ankylosing spondylitis is linked to Klebsiella—the evidence,” Clinical Rheumatology, vol. 26, no. 6, pp. 858–864, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Jacques and D. McGonagle, “The role of mechanical stress in the pathogenesis of spondyloarthritis and how to combat it,” Best Practice and Research: Clinical Rheumatology, vol. 28, no. 5, pp. 703–710, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Uccelli, L. Moretta, and V. Pistoia, “Mesenchymal stem cells in health and disease,” Nature Reviews Immunology, vol. 8, no. 9, pp. 726–736, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. M. C. Stewart and A. A. Stewart, “Mesenchymal stem cells: characteristics, sources, and mechanisms of action,” Veterinary Clinics of North America—Equine Practice, vol. 27, no. 2, pp. 243–261, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Y. Sun, H. Y. Zhang, X. B. Feng, Y. Y. Hou, L. W. Lu, and L. M. Fan, “Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus,” Lupus, vol. 16, no. 2, pp. 121–128, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. J. A. Pérez-Simón, S. Tabera, M. E. Sarasquete et al., “Mesenchymal stem cells are functionally abnormal in patients with immune thrombocytopenic purpura,” Cytotherapy, vol. 11, no. 6, pp. 698–705, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. Z. Xie, P. Wang, Y. Li et al., “Imbalance between bone morphogenetic protein 2 and noggin induces abnormal osteogenic differentiation of mesenchymal stem cells in ankylosing spondylitis,” Arthritis and Rheumatology, vol. 68, no. 2, pp. 430–440, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Brenner, H. Blaser, and T. W. Mak, “Regulation of tumour necrosis factor signalling: live or let die,” Nature Reviews Immunology, vol. 15, no. 6, pp. 362–374, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Gratacos, A. Collado, X. Filella et al., “Serum cytokines (IL-6, TNF-α, IL-1 β and IFN-γ) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity,” British Journal of Rheumatology, vol. 33, no. 10, pp. 927–931, 1994. View at Google Scholar
  15. N. Barkham, L. C. Coates, H. Keen et al., “Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis,” Annals of the Rheumatic Diseases, vol. 69, no. 11, pp. 1926–1928, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Callhoff, J. Sieper, A. Weiss, A. Zink, and J. Listing, “Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis,” Annals of the Rheumatic Diseases, vol. 74, no. 6, pp. 1241–1248, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Wang, F. Du, and X. Wang, “TNF-α induces two distinct caspase-8 activation pathways,” Cell, vol. 133, no. 4, pp. 693–703, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. B. Favaloro, N. Allocati, V. Graziano, C. Di Ilio, and V. De Laurenzi, “Role of apoptosis in disease,” Aging, vol. 4, no. 5, pp. 330–349, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. X. Li, L. Liu, D. Meng et al., “Enhanced apoptosis and senescence of bone-marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus,” Stem Cells and Development, vol. 21, no. 13, pp. 2387–2394, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. G. R. Screaton, J. Mongkolsapaya, X.-N. Xu, A. E. Cowper, A. J. McMichael, and J. I. Bell, “TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL,” Current Biology, vol. 7, no. 9, pp. 693–696, 1997. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Szegezdi, A. O'Reilly, Y. Davy et al., “Stem cells are resistant to TRAIL receptor-mediated apoptosis,” Journal of Cellular and Molecular Medicine, vol. 13, no. 11-12, pp. 4409–4414, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Walczak, M. A. Degli-Esposti, R. S. Johnson et al., “TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL,” EMBO Journal, vol. 16, no. 17, pp. 5386–5397, 1997. View at Publisher · View at Google Scholar · View at Scopus
  23. J.-L. Bodmer, N. Holler, S. Reynard et al., “TRAIL receptor-2 signals apoptosis through FADD and caspase-8,” Nature Cell Biology, vol. 2, no. 4, pp. 241–243, 2000. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Van Der Linden, H. A. Valkenburg, and A. Cats, “Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria,” Arthritis and Rheumatism, vol. 27, no. 4, pp. 361–368, 1984. View at Publisher · View at Google Scholar · View at Scopus
  25. D. C. Colter, R. Class, C. M. DiGirolamo, and D. J. Prockop, “Rapid expansion of recycling stem cells in cultures of plastic-adherent cells from human bone marrow,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 7, pp. 3213–3218, 2000. View at Publisher · View at Google Scholar · View at Scopus
  26. D. Li, P. Wang, Y. Li et al., “All-Trans Retinoic Acid Improves the Effects of Bone Marrow-Derived Mesenchymal Stem Cells on the Treatment of Ankylosing Spondylitis: An In Vitro Study,” Stem Cells International, vol. 2015, Article ID 484528, 10 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Fu, H. Ren, Y. Wang, E. Fei, H. Wang, and G. Wang, “DJ-1 inhibits TRAIL-induced apoptosis by blocking pro-caspase-8 recruitment to FADD,” Oncogene, vol. 31, no. 10, pp. 1311–1322, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Wang, Y. Li, L. Huang et al., “Effects and safety of allogenic mesenchymal stem cell intravenous infusion in active ankylosing spondylitis patients who failed NSAIDs: a 20-week clinical trial,” Cell Transplantation, vol. 23, no. 10, pp. 1293–1303, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. Y. Mei, F. Pan, J. Gao et al., “Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis,” Clinical Rheumatology, vol. 30, no. 2, pp. 269–273, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. R. J. François, L. Neure, J. Sieper, and J. Braun, “Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor α in two patients with early disease and transforming growth factor β in three more advanced cases,” Annals of the Rheumatic Diseases, vol. 65, no. 6, pp. 713–720, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Braun, M. Bollow, L. Neure et al., “Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis,” Arthritis and Rheumatism, vol. 38, no. 4, pp. 499–505, 1995. View at Publisher · View at Google Scholar · View at Scopus
  32. U. Lange, J. Teichmann, and H. Stracke, “Correlation between plasma TNF-alpha, IGF-1, biochemical markers of bone metabolism, markers of inflammation/disease activity, and clinical manifestations in ankylosing spondylitis,” European Journal of Medical Research, vol. 5, no. 12, pp. 507–511, 2000. View at Google Scholar · View at Scopus
  33. L. Zhao, J. Huang, H. Zhang et al., “Tumor necrosis factor inhibits mesenchymal stem cell differentiation into osteoblasts via the ubiquitin E3 ligase Wwp1,” Stem Cells, vol. 29, no. 10, pp. 1601–1610, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. L. Chiossone, R. Conte, G. M. Spaggiari et al., “Mesenchymal stromal cells induce peculiar alternatively activated macrophages capable of dampening both innate and adaptive immune responses,” STEM CELLS, vol. 34, no. 7, pp. 1909–1921, 2016. View at Publisher · View at Google Scholar
  35. S. Nagata, “Apoptosis and autoimmune diseases,” Annals of the New York Academy of Sciences, vol. 1209, no. 1, pp. 10–16, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. M. S. Sheikh, T. F. Burns, Y. Huang et al., “p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor,” Cancer Research, vol. 58, no. 8, pp. 1593–1598, 1998. View at Google Scholar · View at Scopus
  37. S. Shirley, A. Morizot, and O. Micheau, “Regulating TRAIL receptor-induced cell death at the membrane: a deadly discussion,” Recent Patents on Anti-Cancer Drug Discovery, vol. 6, no. 3, pp. 311–323, 2011. View at Publisher · View at Google Scholar · View at Scopus